Stage (next event)
Phase 2 (Corporate Update)
Catalyst Info & Data Links
TITLE: Zygel (ZYN002 CBD Gel) for Developmental and epileptic encephalopathies (DEE) - Corporate Update
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Q4 2020 (see slide 4)
05-26-2020 Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session
2020: Cannabidiol Transdermal Gel in Children and Adolescents With Developmental and Epileptic Encephalopathies: An Open-Label Clinical Trial (BELIEVE). American Academy of Neurology (AAN) Science Highlights Virtual Session.
2020: Quality of Life and Qualitative Caregiver Assessments in Children and Adolescents with Developmental and Epileptic Encephalopathies Treated With Cannabidiol Transdermal Gel: An Open-Label Clinical Trial (BELIEVE). American Academy of Neurology (AAN) Science Highlights Virtual Session.
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
Zygel is the first and only pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. Zygel is being developed for patients suffering from FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE) (Learn more HERE).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post